Serina Therapeutics to Present at the 14th Annual Injectables Summit
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, announced its participation in the 14th Annual Injectables Summit in Boston, MA. The company's Chief Development Officer, Randall Moreadith, MD, PhD, will present alongside Enable Injections' Chief Commercial Officer Matthew Huddleston.
Their joint presentation, titled 'Patient-enabled Therapy for Advanced Parkinson's Disease', will focus on the collaboration between Serina's SER-252 and Enable Injections' enFuse Wearable Drug Delivery Platform. This partnership aims to provide advanced Parkinson's Disease patients with life-changing therapeutics through comfortable and convenient delivery methods.
Serina Therapeutics is known for developing its proprietary POZ Platform™ drug delivery technology, which is likely to be a key component in this collaborative effort to improve patient care and treatment outcomes.
Serina Therapeutics (NYSE American: SER), un'azienda biotech in fase clinica, ha annunciato la sua partecipazione al 14° Summit Annuale sugli Iniettabili che si svolgerà a Boston, MA. Il Chief Development Officer dell'azienda, Randall Moreadith, MD, PhD, presenterà insieme a Matthew Huddleston, Chief Commercial Officer di Enable Injections.
La loro presentazione congiunta, intitolata 'Terapia abilitata dai pazienti per la malattia di Parkinson avanzata', si concentrerà sulla collaborazione tra il SER-252 di Serina e la Piattaforma di Somministrazione Farmaceutica Wearable enFuse di Enable Injections. Questo partenariato mira a fornire ai pazienti affetti da malattia di Parkinson avanzata terapie trasformative attraverso metodi di somministrazione comodi e pratici.
Serina Therapeutics è conosciuta per lo sviluppo della sua tecnologia di somministrazione di farmaci proprietaria POZ Platform™, che si prevede sarà un elemento chiave in questo sforzo collaborativo per migliorare l'assistenza ai pazienti e i risultati terapeutici.
Serina Therapeutics (NYSE American: SER), una compañía biotecnológica en etapa clínica, anunció su participación en el 14º Summit Anual de Inyectables en Boston, MA. El Director de Desarrollo de la compañía, Randall Moreadith, MD, PhD, presentará junto al Director Comercial de Enable Injections, Matthew Huddleston.
Su presentación conjunta, titulada 'Terapia habilitada por el paciente para la enfermedad de Parkinson avanzada', se centrará en la colaboración entre el SER-252 de Serina y la Plataforma de Administración de Medicamentos Wearable enFuse de Enable Injections. Esta asociación tiene como objetivo proporcionar a los pacientes con enfermedad de Parkinson avanzada terapias que cambian la vida mediante métodos de entrega cómodos y convenientes.
Serina Therapeutics es conocida por desarrollar su tecnología de administración de medicamentos patentada POZ Platform™, que probablemente será un componente clave en este esfuerzo colaborativo para mejorar la atención y los resultados del tratamiento de los pacientes.
Serina Therapeutics (NYSE American: SER), 임상 단계의 생명공학 회사는 매사추세츠주 보스턴에서 열리는 제14회 연례 주사제 서밋에 참여한다고 발표했습니다. 회사의 개발 담당 최고 책임자 Randall Moreadith, MD, PhD는 Enable Injections의 최고 상업 책임자 Matthew Huddleston와 함께 발표할 예정입니다.
그들의 공동 발표 제목은 '환자 주도의 고급 파킨슨병 치료'로, Serina의 SER-252와 Enable Injections의 enFuse 웨어러블 약물 전달 플랫폼 간의 협력에 중점을 두고 있습니다. 이 파트너십은 고급 파킨슨병 환자들에게 편안하고 편리한 전달 방법을 통해 삶을 변화시키는 치료법을 제공하는 것을 목표로 합니다.
Serina Therapeutics는 환자 치료와 치료 결과 향상을 위한 협력 노력을 위한 핵심 요소가 될 것으로 예상되는 자사 고유의 POZ Platform™ 약물 전달 기술을 개발한 것으로 알려져 있습니다.
Serina Therapeutics (NYSE American: SER), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation au 14ème Sommet Annuel sur les Injections à Boston, MA. Le Directeur du Développement de l’entreprise, Randall Moreadith, MD, PhD, présentera aux côtés de Matthew Huddleston, Directeur Commercial de Enable Injections.
Leur présentation conjointe, intitulée 'Thérapie habilitée par le patient pour la maladie de Parkinson avancée', se concentrera sur la collaboration entre le SER-252 de Serina et la Plateforme de Distribution de Médicaments Portable enFuse d'Enable Injections. Ce partenariat vise à offrir aux patients atteints de maladie de Parkinson avancée des thérapies qui changent la vie grâce à des méthodes de livraison confortables et pratiques.
Serina Therapeutics est reconnue pour le développement de sa technologie de livraison de médicaments propriétaire POZ Platform™, qui devrait jouer un rôle clé dans cet effort collaboratif pour améliorer les soins aux patients et les résultats des traitements.
Serina Therapeutics (NYSE American: SER), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme am 14. jährlichen Injektables Summit in Boston, MA, angekündigt. Der Chief Development Officer des Unternehmens, Randall Moreadith, MD, PhD, wird gemeinsam mit Matthew Huddleston, dem Chief Commercial Officer von Enable Injections, präsentieren.
Ihre gemeinsame Präsentation mit dem Titel 'Patientenbefähigte Therapie für fortgeschrittene Parkinsonkrankheit' wird sich auf die Zusammenarbeit zwischen Serinas SER-252 und Enable Injections' enFuse Wearable Drug Delivery Platform konzentrieren. Diese Partnerschaft zielt darauf ab, Patienten mit fortgeschrittener Parkinsonkrankheit lebensverändernde Therapeutika durch komfortable und praktische Liefermethoden bereitzustellen.
Serina Therapeutics ist bekannt für die Entwicklung ihrer proprietären POZ Platform™-Medikamentenabgabetechnologie, die voraussichtlich ein Schlüsselelement in diesem gemeinsamen Bemühen ist, die Patientenversorgung und Behandlungsergebnisse zu verbessern.
- None.
- None.
HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 14th Annual Injectables Summit in Boston, MA.
The joint presentation, with Enable Injections’ Chief Commercial Officer Matthew Huddleston, is entitled “Patient-enabled Therapy for Advanced Parkinson's Disease - A Case Study with Serina Therapeutics' SER-252 + Enable Injections' enFuse Wearable Drug Delivery Platform”. Dr. Moreadith and Mr. Huddleston will share how their teams are partnering together to provide life-changing therapeutics with comfortable and convenient delivery to those living with advanced Parkinson’s Disease.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K for the year ended December 31, 2023, Serina’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and Serina’s other periodic reports and documents filed from time to time with the SEC.
The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Investor.relations@serinatherapeutics.com
(256) 327-9630
FAQ
What is Serina Therapeutics presenting at the 14th Annual Injectables Summit?
Who is presenting on behalf of Serina Therapeutics (SER) at the Injectables Summit?
What is the focus of Serina Therapeutics' (SER) collaboration with Enable Injections?
What is Serina Therapeutics' (SER) proprietary technology mentioned in the press release?
